A drug discovery startup company or academic lab entering the screening arena faces numerous challenges as it tries to manage the large quantity of data generated by a typical drug discovery screening campaign. Although there are sophisticated off-the-shelf software solutions available, their use requires substantial forethought and attention to detail if the data they capture are to be of sufficient quality to serve the various purposes to which it will be put. For newcomers to the field of screening data management in particular, the problem is compounded by a lack of literature covering the practical aspects of managing screening data. The authors provide some practical advice based on their experience of using a commercially available software suite. They discuss issues ranging from the organizational aspects to examples of how the form and content of metadata can have a big impact on whether results can be easily queried, pivoted, and reported. It is also hoped that their experiences might provide an opportunity for reflection to data management practitioners operating in established environments. (Journal of Biomolecular Screening 2009:999-1007 
INTRODUCTION
S creening is one of the important processes used in the pharmaceutical industry to discover drugs. Small molecules (or natural products) are tested ("screened") for their ability to modulate target proteins or to alter key cellular or physiological properties. At the onset of industrial drug discovery in the 1950s, compounds were tested in whole animals. Then, during the 1970s, cellular and biochemical assay formats were developed, enabling the testing of larger numbers of chemicals in a more efficient manner. Today, high-throughput screening (HTS) is a widely used technology delivering chemistry entry points for drug discovery programs. Hand-in-hand with an increasing number of compounds being tested and parameters being measured goes an increasing volume of data that need to be captured, managed, and stored for subsequent analyses. High-quality screening results and derived compound knowledge are vital for the success of any company in the pharmaceutical industry. The late-stage attrition of chemical entities in development and beyond is extremely costly, and therefore failures in late stages must be minimized by rigorous, objective quality assessment at key points in the discovery process (for a more detailed review, see, e.g., Bleicher et al. 1 and Pereira and Williams 2 ).
HTS has also become increasingly important in academic research, where the need for effective ways to capture, analyze, quality control, and report on every aspect of an experiment has grown significantly. The NIH roadmap initiative 3 is providing funding and opportunities to harness academic insights and expertise to fully capitalize on HTS technologies for biological research. However, the flexibility and diversity of the HTS process make it one of the least standardized activities carried out in academia today. 4 Closely connected with the increasing demand for HTS in academic and pharmaceutical laboratories, a number of drug discovery data management and data analysis solutions have been developed. 5, 6 In recent years, a number of publications have appeared on the subject of screening informatics. Many of these deal with general issues at a high level: the importance of quality control (QC) for data normalization and reliability, 5 data integration, 7 how to turn information (screening data) into knowledge, 8 and how to use information for decision making. 8, 9 Others begin to touch some of the more practical issues that must be faced both at the level of managing screening data 6 and reporting screening data in publications. 4, 9 Yet other efforts are under way that aim to standardize the minimal data that need to be reported in publications and, in future, in public databases (Minimum Information About a Cellular Assay [MIACA]). The current MIACA draft document 10 describes the "minimum" information that must or should be reported to allow comparison of results emanating from diverse sources. Recently, Soldatova and coauthors 11 presented an ontology called EXACT, which aims to provide researchers with the means to describe biomedical assays such that they can be faithfully reproduced by others.
There is, however, very little literature on the practical issues of setting up and managing a data capture system to meet the needs of a small to medium drug discovery organization. Here, we provide some practical advice on the management of screening data based on our experience of using a commercially available software suite (ActivityBase from IDBS Ltd.) to support compound registration and screening activities. Our experience has been largely with 96-and 384-well plate-based screening of hundreds to thousands of compounds per day (traditionally termed high-throughput screening; http://www .sbsonline.com/links/terms.php). However, we also apply the same concepts to lower throughput assays and screens.
We identify 3 key phases that can characterize the process of managing screening data ( Fig. 1) :
• Understanding the purposes for which the screening data will be used. This we characterize as the destination. • Shaping the environment in which the screening data will be managed. This we characterize as organization. • Configuring the system to manage the screening data. This we characterize as the implementation.
It is important to point out that, although these phases can be conceptually organized in a sequential manner, in practice, there is a process of continual improvement and adaptation to changing requirements. This means that elements of preceding or succeeding phases may need to be reviewed and revised. However, expending more effort at the beginning on the destination and organization phases should result in more quickly achieving a system that delivers what is required.
DESTINATION: WHERE ARE YOU GOING?
It helps to be as clear and precise as possible about the purposes for which screening data will be used. This may seem like an obvious point but, in our experience, during the early days of setting up a screening organization, the data management requirements are relatively underdeveloped. With time, the requirements become clearer, and the data management system is developed to accommodate new needs.
In our case, it took approximately 3 years to reach a state where the need to change or capture additional results or metadata diminished to an occasional occurrence. Typically, data captured in the early days of the system's usage were not as sophisticated as that captured later on. Expending some additional effort at the outset to understand the uses to which screening data will be put will help minimize the time required to reach such a stable state.
The details of the recorded results and their context significantly affect the reporting possibilities. In particular, appropriate pivoting is a critical operation that can make the difference between a clear report that was easy to produce and one that is neither clear nor easy to compile. Understanding the reporting requirements of projects will help identify the results and results context that are required to query, pivot, and report data to meet their needs.
On a day-to-day basis, the questions that need to be answered are likely to include the following: Which new plates need to be screened today? Which plates need to be rescreened because of control problems? Which compounds need to be reordered for confirmation of compound activity? Information must be captured that helps to answer such questions at the level of an individual assay. For example, information can be captured indicating that a compound was tested, but for technical reasons, the assay could not be trusted. In addition, metadata can be captured to indicate that a particular result was produced either as a first test to identify an active compound or as a confirmation of a previously identified active. Without capturing this information explicitly, it is difficult to report a compound's progress in an easy to understand form (see Fig. 2 ).
Beyond the management of a single assay, a research group or project team might need to manage the progression of compounds through the set of assays (often referred to as the screening cascade) defined as important for the project based on the various predefined decision points. At this level, the questions that need to be asked could include the following: Which compounds are active in assay X? Which active compounds have passed QC? What is the solubility or chemical or metabolic profile for the active compounds? Which compounds should proceed to IC 50 determination? Which compounds should go through a specificity or selectivity assay? At this level, the information that needs to be recorded includes obvious results such as average percent inhibition values, IC 50 values, curve top and bottom, Hill slope, and so on. However, it can also be useful to capture additional context regarding the screening cascade for the particular project. Capturing, for example, information such as whether the results for a particular target or cell line are for the primary screen, selectivity screen, or some other purpose (e.g., cytotoxicity or cell motility) has a number of benefits. It allows results to be reported in a clear manner, showing progression through the screening cascade. This can be particularly useful for those who may not be intimately familiar with reasons for screening particular targets or cell lines. It also facilitates querying.
Beyond the immediate requirements of research groups and screening teams, at some point, screening data might be used in data-mining activities. Some requirements may be obvious from the start: for example, how to identify compounds active in all assays (frequent hitters) or the need to identify profiles associated with "active" compounds. Other questions may not be known at the time the data are captured, however, making it difficult to know what, if any, additional information beyond that necessary to manage the project will be required. A balance must be struck between attempting to capture every possible item of information and capturing the bare minimum.
Data that provide information on result quality are one obvious possibility to consider. Examples of the kind of information we chose to capture include the number of concentrations used for an IC 50 , whether curve-fitting parameters were locked, the number of replicates used, some details of the plate reader used, the date the assay was performed, and so on. Over the longer term (e.g., the course of a screen), one may also be required to perform a quality control of the assay (e.g., to identify drift effects that are not visible from one day to the next). In this case, it will be necessary to capture appropriate results for the controls, such as the mean of the raw positive and negative control readings. Most likely, it is a requirement to associate results with a particular batch of a compound structure. However, it might also be prudent to record batch information on important assay constituents, such as a cell line, as well as constituents of the controls used in normalization. Although this information is unlikely to be used on a daily basis, in the event that quality problems are subsequently identified with a particular assay constituent, this information will permit affected results to be identified.
ORGANIZATION: HOW DO YOU PLAN TO GET THERE?
The environment in which screening data will be captured and managed is an important factor that has a significant impact on the data management process. Key aspects of this environment include the choice of software, the distribution and allocating of responsibilities, identification of the scope of the data to be managed, standardization of the concepts and language used to describe screening assays, standardization of data import protocols, and standardization of the system's usage.
Choice of software and database system
Our advice is buy, do not build. Building a system in-house is unlikely to be the core business of a small to medium drug discovery organization. Notwithstanding the restrictions inherent in using a commercial product, buying is likely to be the most productive strategy. A number of commercial products are available that provide most of what is needed to manage compound screening data (for more information, see, e.g., Ling 6 ). Opensource systems are also becoming available (see, e.g., see M-Screen 12 ). We do not attempt a review here. Such systems capture results in an underlying relational database, with Oracle being the de facto standard. Independently of which system is used, there are likely to be some requirements that are not sufficiently met, so be prepared for some custom application building or purchase and integration of additional tools to fill the gaps.
Another important aspect to consider early on is whether a single system will be used to capture, manage, query, and report the data or whether primary captured data will be extracted into a secondary system such as a screening data mart or data warehouse. There are pluses and minuses on both sides. At the outset, a single system is an attractive option; it is cheaper, easier to set up, and simpler to maintain. However, over time, a number of factors come into play that may make a screening data mart an attractive option. The accumulation of small changes to the structure and format of captured results leads to increasing complexity and difficulty in performing queries and generating reports. In addition, the quantity of data captured is constantly increasing, and there is therefore a tendency for database performance to decrease over time. This decrease in performance can be countered to some extent by database tuning, the purchase of additional memory, and so on. However, the need for data consolidation, although absent early on, is likely to grow over time. Clearly, the rate at which this need asserts itself and whether it reaches a point where action is required depends on many factors, and whether or when to initiate such a consolidation will, of course, differ for every organization. Our advice is to periodically review the need to consolidate primary screening data in, for example, a data mart or data warehouse.
Organization of work
Whichever system is used, result capture protocols must be developed for the various assays in use. Such protocols specify the results and associated metadata to be captured in the database and perform various calculations, including curve fitting. An off-the-shelf system will provide the tools to do this such that little or no code need be written. However, the tools provided must be used to implement the capture of data that makes sense to the organization. In our experience, delegation of this responsibility should be done with care. The tools may have been designed to be used by the bench scientist, but without strong informatics input, it is difficult to maintain adequate control of data quality.
Initially, responsibility for developing protocols was carried out in a decentralized manner by the scientists responsible for developing and running the assays. However, this resulted in a rapid diversity and use of result types and captured context to meet the needs of specific assays, with little account taken of broader informatics issues. In particular, the ability to query and report results across multiple assays and projects with an assurance data compatibility was not taken into consideration sufficiently. Subsequently, the development of data capture protocols was centralized within an informatics group with information management expertise. Close cooperation was established between the informaticians, scientists, and statisticians, and development and usage of the system were standardized with a very significant improvement in data quality.
Get agreement on which assays are to be captured by the system
There is a variety of assay types, the results of which (and here wet lab results, not predictions, are intended) could be captured by a screening data management system. Capturing as many kinds of assay results as is practically possible within a single system has the very significant advantage that the task of querying all known results for a given compound is greatly simplified. The small effort to capture a single numerical endpoint or categorical result, along with the important conditions for a low-throughput assay outsourced to contract research organizations (CROs), is worth it, in our opinion. If this information is not available in the database, you can be sure that somebody will want to manually add it to a spreadsheet, combine it with other assay results, and probably load them all into a graphical visualization tool.
Establish a common understanding regarding the identification of controls
The development of result capture protocols-and ultimately the classification of compounds according to their activity-is intimately bound to the identification and meaning attached to the control samples used in an assay, particularly the positive and negative controls. Clearly, many other elements of screening assays also could or should be the subject of a common understanding. However, in our experience, the identification of positive and negative controls is the one aspect that has the most potential to cause confusion. As indicated by Ling, 6 these terms can be highly ambiguous and context dependent. After experiencing a number of such instances, we agreed on some simple definitions. These terms, as well as many others, are the subject of the Society for Biomolecular Sciences (SBS) glossary of screening terms, and we recommend their adoption (http://www.sbsonline.com/links/terms.php).
Develop a strategy and framework for describing biological assays
Biological assays are complicated entities. They can be described and characterized in a large number of ways:
• Business context-that is, the purpose for which they are being used in a particular project or screening cascade (primary screen, counter screen, selectivity or specificity screen, metabolic profiling screen, etc.)
• Biological process of interest, whether at the protein (binding or function modulation), intracellular (e.g., calcium flux or membrane potential), intercellular (e.g., cell motility, cell growth, apoptosis), tissue, or organism (e.g., behavior) level • Desired compound activity (e.g., enzyme inhibitor or activator, receptor agonist, or antagonist) • Sample type (e.g., cell based, cell-free multicomponent, isolated molecular target) • Biological components or constituents of particular interest, which may include the cell line, the target, the substrate, or the transcription factor • Technology (e.g., enzyme-linked immunosorbent assay
[ELISA], surface plasmon resonance [SPR], fluorescence resonance energy transfer [FRET])
The definition and classification of such kinds of information is the subject of ontology. In recent years, the development and use of bio-ontologies for various purposes has grown dramatically. Blake 13 cites the goals of clarifying scientific discussion and extending the power of computational approaches and systems to perform data exploration, inference, and mining. Bard and Rhee 14 discuss the representation of knowledge in a computer-comprehensible way, interoperability across databases, and the annotation of large-scale data with ontology IDs. A number of ontologies or ontology-related efforts touch on the description of drug discovery-related assay data, including Drug Interaction Ontology, 15 IntAct, 16 EXACT, 11 and MIACA. 10 All these efforts, however, aim at goals way beyond those of a small to medium drug discovery company or academic research laboratory. In one way or another, they aim at reducing the ambiguity and increasing the formality of information in the public domain.
However, developing a simple but consistent approach to describing biological assays can have benefits (e.g., see the simple assay-type categorization of Sirois and Cloutier 17 ). Different users typically refer to assays from their different points of view depending on their background-for example, one person referring to the assay via the manufacturer's kit name, another by the phenotype of interest, and yet another by the role of the assay in a given project. For the purpose of tracking a compound through the screening cascade, it is only important that the results for each assay are distinguishable and the name of each assay is recognizable to the users of the data. However, we feel that developing a standard and consistent approach to naming assays and possibly compiling a canonical list of assay names in use would help facilitate understanding, particularly during the process of planning, prioritizing, and scheduling the implementation of result capture protocols.
Second, it should help the identification of those features, which might be important to capture for future data-mining activities. Attempting to capture every last detail of an assay will lead to complex and resource-intensive protocol development. The task of managing and querying results on a daily basis may also become increasingly complicated. A compromise must be made between explicitly capturing all potentially relevant information about an assay and capturing only a reference to the assay system and the critical variable parameters, such as target and cell line. The compromise between these 2 extremes must be sensitive to the needs of the various interested parties. These include the people responsible for running the assay and capturing the results, the project team members who need to access the final and verified results, and "future data miners" whose full needs might not yet be known. To make such a compromise, a good understanding of the type and structure of assay-relevant information is required.
Standardization of data import protocols
Unfortunately, the centralization of protocol and template development is unlikely to be sufficient to ensure that a high quality of data capture is maintained over time. Capturing decisions, guidelines, and rules regarding the development and use of data capture protocols in a standard operating procedure (SOP) document will help ensure that these are visible and available to all people involved. An SOP can provide the framework within which to take decisions regarding which data are to be captured. Moreover, the document provides a method for managing change. As requirements change-for example, due to experience, new technologies, and new ideas-it is most likely that the approach to capturing screening data will change over time. In our experience, this is inevitable. To ensure that new ideas, practices, or decisions taken at any point in time are not forgotten or not continued into the next project or assay or are implemented in a nonstandardized way, one should periodically release a new version of the document.
We have found it useful to include in our SOP aspects such as the minimum results and conditions to be captured for various types of assays, standard calculations, the usage of controlled vocabulary, and the responsibilities of the users, particularly regarding manual annotation and flagging of results and control of curve fitting. Naturally, these data analysis aspects can also be captured in dedicated SOPs; what is important is that these aspects are documented.
Business rules
Definition of business rules regarding the capture of screening results is an important consideration. One that we considered particularly important was the extent to which users are permitted to intervene in curve fitting and annotation of results.
When performing high-throughput assays, it may be more efficient to automate all calculations and annotations based on predefined business rules. However, with lower throughput (tens of thousands of compounds per screen), our experience is that the ability of end users (bench scientists) to manually intervene to maximize the information content and therefore value out of the screen is an attractive option. This could include, for example, manually removing outliers in the controls (over and above those that easily can be removed automatically), knocking out outliers on an IC 50 curve, locking a parameter to a fixed value, or manually selecting an alphanumeric value to flag a particular aspect of an IC 50 curve.
This question should be decided early on so that rules and guidelines can be set in place specifying what the user is able to influence and how he or she should go about it. These rules are required to ensure not only that all protocols and templates are implemented in a standard way but that users also use them in a standard way. If there is no control over how and when such manual intervention is performed, then there is no guarantee that results will be comparable.
We chose to routinely perform automatic knockout of outliers in concentration-response curves. In addition, we encourage users to manually knock out the occasional outlier missed by the automatic method. On top of this, we have implemented a method of enabling users to knock out 1 or more replicates within the controls. We also give users the option of modifying parameters used in curve fitting (e.g., locking and prefitting of IC 50 parameters). As far as possible, these user interventions are also captured, for example, by the number of data points used to fit a curve in addition to the original number of replicates and concentration points.
End user training
Standardizing protocol development and implementing business rules are important. It is equally important, however, that users have an adequate understanding of the results that are captured, including when and how to use them. The reporting of concentration-response results is a good example.
Concentration-response results (e.g., IC 50 or EC 50 values) are important in drug discovery as they are an easily obtainable measure of a compound's potency. They are typically used to define hit compounds and to guide medicinal chemistry efforts during a structure-activity relationship (SAR) program where the aim is to improve the compound. Based on the assays employed for concentration-response studies, further important parameters also can be obtained such as a compound's efficacy. Such additional parameters are important as well to guide an SAR study, as a less potent compound with high efficacy might be favorable compared to a compound with higher potency but only low efficacy. Thus, it is important to store not only numerical IC 50 or EC 50 values but also these other parameters where possible.
The approach we have found useful is to store all the parameter values calculated by the curve-fitting algorithm (e.g., curve top, curve bottom, Hill slope, and the IC 50 or EC 50 , assuming a 4-parameter model). It is also helpful to complement these numerical values by the addition of 1 or more categorical results that flag distinctive behaviors of the fitted curve, such as a nonsigmoidal response or curve bottom out of range. This approach requires a certain amount of training among the users of the results to ensure that the correct queries are performed for the purpose at hand.
IMPLEMENTATION: WHAT WILL YOU BUILD TO GET THERE?
So far, we have discussed the strategic and organizational aspects of managing screening data. We have hinted at a number of numerical and alphanumeric results and metadata that we have found useful to capture. Some of these we captured at the outset and others we added at a later date. Here we provide a summary of the more important results and metadata that we have found useful along with an explanation of why. We focus on categorical results as the numerical ones are mostly obvious. Figure 2 also shows how some of these might be used to report the progress of compounds through a screening cascade.
Results
Assay flag. This is a categorical result that indicates that a compound was tested in a particular assay but that, for technical reasons, the numerical results were not trustworthy (values include OK, INVALID). For example, a plate well was empty or the controls did not behave as expected. It serves to indicate to the screening unit that a compound may need to be retested. Where a compound in a particular assay run is flagged as invalid, no additional results, other than perhaps a free text comment or flags for the controls, are saved.
Action flag. This is a categorical result that indicates whether a compound was considered active or inactive in a particular assay. Although a compound's activity or inactivity can be deduced, typically from an average percentage activity value and a threshold, the method of arriving at a threshold may require sophisticated statistical analysis. Flagging the compound explicitly serves to record a decision based on proper analysis and provides the project team with the necessary information to stop or continue a compound's progression.
IC 50 flag (also applies to EC 50 flag, KI flag, etc.). This is a categorical result used to record any notable features of a technically valid run of a concentration-response assay. A value of OK indicates that the fitted concentration-response curve has a classical sigmoidal shape, the calculated IC 50 value lies within the range of tested concentrations, and the curve top and bottom indicate complete or nearly complete inhibition (in the case of an IC 50 ) with respect to the controls. Some other aspects of the fit may simply need to be flagged and may not bring into doubt the IC 50 value itself-for example, the curve top or bottom being outside of a preset range. Yet other flag values are used to indicate more serious problems that may bring the IC 50 value into doubt-for example, an IC 50 value extrapolated beyond the range of tested concentrations or a nonsigmoidal response or no concentration response. For issues such as these, we typically do not store the numerical IC 50 or other parameter values even where the model is able to calculate them.
Result context
Result context is that information required to make sense of numeric or categorical results. It includes the obvious conditions of an assay such as the compound concentration, the target, or the cell line. It also includes such things as the project for which the results are being captured and the name of the data capture protocol, items that are captured automatically in the system we use (ActivityBase from IDBS). Here we focus on those aspects of the result context that were less obvious at the outset but that we discovered to be very useful for the purpose of querying and reporting of results.
Assay description. This is a categorical condition that identifies the assay system used (and is subject to all of the difficulties mentioned above). It is a condition whose original purpose was to indicate minor changes in an assay that were not captured explicitly elsewhere. However, we have come to use it as the unique identifier for the assay system. Frequently, the same information is captured in the name of the data import protocol. However, depending on circumstances, there may be occasions when it is desired to use a single data import protocol for different assays. In this case, an independent method is required to distinguish the assay system used to generate results. We have also found another benefit; we typically write one data import protocol for single concentration data and another for concentrationresponse data because this is technically most convenient. Having an independent way to annotate the assay system allows the results to be pivoted and grouped in a more useful way (see Fig. 2 ).
Screening purpose. This is a categorical condition used to indicate the purpose of the assay within a particular screening cascade. Values assigned to this condition include PRIMARY SCREEN, COUNTER SCREEN, SPECIFICITY SCREEN, and so on. This condition probably does not provide any additional information that cannot be deduced from other conditions, such as the assay system, the target, and the cell line. Occasionally, a change in a project's strategy may result in an assay that was once used as a secondary assay to be reused as a primary assay. In this case, this condition captures this fact explicitly. The existence of this condition also makes constructing queries for the results easier, especially when the queries are built by someone not intimately familiar with the project's scientific details. In addition, the condition enables instantly comprehensible reports to be generated (see Fig. 2 ).
Screening step. Identification of compounds active in a given assay is frequently a 2-step process. Active compounds are initially identified in a first test, and then they are confirmed in a second. To facilitate reporting of results, we capture this information in a categorical condition called the screening step. The condition takes the values of ACTIVE IDENTIFICATION, ACTIVE CONFIRMATION, and HIT IDENTIFICATION. Without capturing this information explicitly, it would not be possible to pivot the results into 2 columns for the purpose of reporting screening progress. Nor would it be easy to query for results generated only in the first test or only in the second confirmation test. We found the ability to do this useful for the purpose of performing statistical analyses.
Replicate. This is a numeric condition that we use to indicate the replicate number of a compound in a well on a plate. For example, in a single concentration plate, there may be duplicates or triplicates on the same plate. Annotating the replicate wells as replicate number 1, 2, or 3, for example, allows the normalized values for each well to be pivoted into 3 adjacent columns of a report. Our users find this very useful when performing a detailed analysis of results.
These results and conditions represent only a selection of those we found particularly useful beyond the more obvious ones. Of course, there are many others not reported here.
CONCLUSION
We have discussed a number of aspects that we suggest should be considered by anyone planning to set up and use a screening data management system in the field of drug discovery. We found it useful to structure this discussion around 3 themes: destination, organization, and implementation. Destination involves understanding where you are going (i.e., what you want to do with the results and data that you will capture). We found it useful to distinguish between the needs of the screening group managing a particular assay, the needs of the project managing a particular screening cascade, and the needs of the organization to discover or mine information across projects and activities. Organization involves thinking about how you will structure the process of capturing results. Important issues include organizing the work of developing data capture protocols, standardizing the development and use of such protocols, and establishing a common language, especially in those areas where there is potential for ambiguity such as the identification of positive and negative controls and the description and naming of assay systems. Implementation covers the system that you will construct to store and access your screening data and includes the identification of specific result types and metadata. An important factor to keep constantly in mind is the extent to which your choices of result types and metadata will enable you to query, pivot, and report the information in useful ways. We provide a summary of some result types and metadata that we found useful beyond the obvious ones.
Along the way, we have had to make compromises-for example, between standardization and flexibility or between capturing all potentially relevant information and capturing the bare minimum. These compromises have been driven by our goals. We have indicated that, for practical reasons, the level of detail required by a framework such as EXACT is beyond the scope of an organization that does not intend to share its screening results in the public domain. However, the need for standardization in the description of biomolecular assays still exists, whether to aid the comparison of results emerging solely from in-house assays, between collaborating parties, or perhaps in future comparison with results in the public domain. We believe that a simple biomolecular assay classification system would be a good thing. Such a framework could be guided, for example, by EXACT, but its purpose would be to provide a standard way of locating assays in the same ballpark such that results were comparable. It would include the most important orthogonal dimensions of assay variability, binding versus functional, reporter gene versus phenotype, process of biological interest, and so on. It would also provide a standard terminology. We believe that such a standard would also facilitate data comparison of results from chemogenomics efforts. Recently, public databases of chemogenomics data have been established, and the lack of sufficient information has been described. 18 We believe that concepts such as those described in this article could be helpful in future attempts at comparing data from different sources or experiments aiming to support drug discovery efforts.
